SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 24, 2002
---------------------------------
(Date of earliest event reported)
ATRIX LABORATORIES, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-18231 84-1043826
---------------------------- --------------------- ---------------------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer Identification No.)
of Incorporation)
2579 Midpoint Drive, Fort Collins, Colorado 80525
------------------------------------------------------------
(Address of principal executive offices, including zip code)
(970) 482-5868
----------------------------------------------------
(Registrant's telephone number, including area code)
Item 5. Other Events.
On January 24, 2002, Atrix Laboratories, Inc. announced that it had
received approval from the U.S. Food and Drug Administration for Eligard(TM)
7.5mg (formerly Leuprogel One-Month Depot), leuprolide acetate for subcutaneous
injection for treatment of advanced prostate cancer.
For more information, see the press release attached hereto as Exhibit
99.1.
Item 7. Exhibits.
99.1 Press Release dated January 24, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ATRIX LABORATORIES, INC.
By: /s/ Brian G. Richmond
--------------------------------------
Brian G. Richmond
Chief Financial Officer
Date: February 4, 2002
EXHIBIT INDEX
EXHIBIT DESCRIPTION
------- -----------
99.1 Press Release dated January 24, 2002